RESEARCH ETHICS AND PATIENT CONSENT
The patient received personalized treatment as participant of the
RESILIENT trial (CTRI/2018/02/011808), which was previously approved by
the Institutional Ethics Committees of Datar Cancer Genetics as well as
HCG Manavata Cancer Centre. All Study Participants provided written
Informed Consent prior to enrolment and sample collection. Study
participants also consented to publication of deidentified data and
findings. The RESILIENT trial was conducted in accordance with existing
Ethical and Regulatory considerations including the Declaration of
Helsinki.